ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Sex-based inequities in non-small cell lung cancer: gaps and opportunities across the care pathway.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSex-related disparities in non-small cell lung cancer (NSCLC) remain incompletely characterized, particularly in low- and middle-income countries. We aimed to evaluate sex-based differences across the entire lung cancer care continuum, from smoking exposure and diagnostic pathways to treatment access and survival outcomes, distinguishing biological susceptibility from healthcare system inequities.
methodsWe conducted a retrospective cohort study of 1031 consecutive patients with histologically confirmed NSCLC managed at two tertiary oncology centers in Tunisia between 2013 and 2023. Smoking exposure, body mass index, age and stage at diagnosis, diagnostic and treatment intervals, access to molecular testing, treatment patterns, and overall survival were compared between women and men. Multivariable regression and interaction analyses were performed.
resultsWomen represented 20.7% of the cohort and were younger at diagnosis (median 54 vs. 62 years; p = 0.02) with lower cumulative smoking exposure. After adjustment for smoking intensity and age, sex was not independently associated with stage at diagnosis. Women experienced longer patient intervals (156 vs. 125 days; p = 0.025) and diagnostic intervals (42 vs. 31 days; p = 0.02), whereas treatment intervals were similar. Women were more likely to undergo molecular biomarker testing and to receive targeted therapy. Median overall survival was longer in women (20 vs. 14 months; log-rank p < 0.01), but no sex-by-stage or sex-by-smoking interaction was identified for survival.
conclusionsSex-related differences in NSCLC are heterogeneous: biological susceptibility drives earlier onset at lower smoking exposure, while prolonged diagnostic delays and under-representation in screening programs reflect addressable healthcare inequities. Targeted interventions are warranted to improve early detection and diagnostic equity in women.
Indexed as
Identifiers
42251629What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.